US2009087450A1PendingUtilityA1

Combination therapy of hybrid cells with BCG injection for treating Cancer Patients

65
Assignee: GREENVILLE HOSPITAL SYSTEMPriority: Jan 11, 2000Filed: May 23, 2007Published: Apr 2, 2009
Est. expiryJan 11, 2020(expired)· nominal 20-yr term from priority
Inventors:Thomas E. WagnerYanzhang Wei
A61K 2039/55594A61K 2039/80A61K 35/74C12N 5/163A61K 35/13A61K 2039/545C12N 5/16A61K 39/0008A61P 37/06A61P 35/00A61K 2035/122A61K 40/42A61K 40/24A61K 40/19A61K 2239/38A61K 2239/31A61K 39/0011A61K 35/15
65
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to cancer treatment compositions and methods for a specific cancer patient population. In particular, the application describes methods of treating a patient with cancer, such as a neuroblastoma, with a hybrid cell preparation in combination with Mycobacterium bovis bacillus Calmette-Guerin (BCG).

Claims

exact text as granted — not AI-modified
1 . A method for treating a patient with cancer comprising co-administering to a patient in need thereof a composition comprising a primary tumor cell fused to a dendritic cell, and  Mycobacterium bovis  bacillus Calmette-Guerin (BCG), wherein the BCG is not mixed with the hybrid cell composition. 
   
   
       2 . The method of  claim 1 , wherein the BCG is not mixed with the hybrid cell composition. 
   
   
       3 . The method of  claim 1 , wherein the patient has stage I, stage II, stage III, or stage IV cancer, wherein the cancer is according to the American Joint Committee on Cancer (AJCC) 2002 Staging System. 
   
   
       4 . The method of  claim 3 , wherein the patient has stage IV cancer. 
   
   
       5 . The method of  claim 3 , wherein the patient has a cancer selected from the group consisting of renal cancer, ovarian cancer, lung cancer, breast cancer, prostate cancer, bladder cancer, colon cancer, skin cancer and neuroblastoma. 
   
   
       6 . The method of  claim 5 , wherein the patient has neuroblastoma. 
   
   
       7 . The method of  claim 1 , wherein the patient has no evidence of disease following surgery, radiation, chemotherapy, or a combination thereof. 
   
   
       8 . The method of  claim 1 , wherein BCG is administered to the patient after administration of the hybrid cell composition. 
   
   
       9 . The method of  claim 8 , wherein BCG is administered to the patient within about 10 minutes of the administration of the hybrid cell composition. 
   
   
       10 . A method for increasing survival of a patient with cancer, comprising co-administering to a patient in need thereof a composition compris a primary tumor cell fused to a dendritic cell, and  Mycobacterium bovis  bacillus Calmette-Guerin (BCG), 
   
   
       11 . The method of  claim 10 , wherein the BCG is not mixed with the hybrid cell composition. 
   
   
       12 . The method of  claim 11 , wherein the patient has stage IV cancer. 
   
   
       13 . The method of  claim 11 , wherein the patient has a cancer selected from the group consisting of renal cancer, ovarian cancer, lung cancer, breast cancer, prostate cancer, bladder cancer, colon cancer, skin cancer and neuroblastoma. 
   
   
       14 . The method of  claim 13 , wherein the patient has neuroblastoma. 
   
   
       15 . The method of  claim 13 , wherein the patient has no evidence of disease following surgery, radiation, chemotherapy, or a combination thereof. 
   
   
       16 . The method of  claim 10 , wherein BCG is administered to the patient after administration of the hybrid cell composition. 
   
   
       17 . The method of  claim 16 , wherein BCG is administered to the patient within about 10 minutes of the administration of the hybrid cell composition. 
   
   
       18 . A method for stimulating an immune response in a patient with cancer, comprising co-administering to a patient in need thereof a composition compris a primary tumor cell fused to a dendritic cell, and  Mycobacterium bovis  bacillus Calmette-Guerin (BCG), wherein the BCG is not mixed with the hybrid cell composition. 
   
   
       19 . The method of  claim 18 , wherein the patient has stage IV cancer. 
   
   
       20 . The method of  claim 18 , wherein the patient has a cancer selected from the group consisting of renal cancer, ovarian cancer, lung cancer, breast cancer, prostate cancer, bladder cancer, colon cancer, skin cancer and neuroblastoma. 
   
   
       21 . The method of  claim 20 , wherein the patient has neuroblastoma. 
   
   
       22 . The method of  claim 20 , wherein the patient has no evidence of disease following surgery, radiation, chemotherapy, or a combination thereof. 
   
   
       23 . The method of  claim 18 , wherein BCG is administered to the patient after administration of the hybrid cell composition. 
   
   
       24 . The method of  claim 23 , wherein BCG is administered to the patient within about 10 minutes of the administration of the hybrid cell composition.

Join the waitlist — get patent alerts

Track US2009087450A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.